BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang M, Wang L, Liu W, Wang T, De Sanctis F, Zhu L, Zhang G, Cheng J, Cao Q, Zhou J, Tagliabue A, Bronte V, Yan D, Wan X, Yu G, Elkord E. Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors. Journal of Immunology Research 2022;2022:1-21. [DOI: 10.1155/2022/2253436] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Yap DRY, Lim JQ, Huang D, Ong CK, Chan JY. Emerging predictive biomarkers for novel therapeutics in peripheral T-cell and natural killer/T-cell lymphoma. Front Immunol 2023;14. [DOI: 10.3389/fimmu.2023.1068662] [Reference Citation Analysis]
2 Saber MM. Coexpression of PD-L1/PD-1 with CXCR3/CD36 and IL-19 Increase in Extranodal Lymphoma. Journal of Immunology Research 2023;2023:1-17. [DOI: 10.1155/2023/4556586] [Reference Citation Analysis]
3 van Geffen C, Heiss C, Deißler A, Kolahian S. Pharmacological modulation of myeloid-derived suppressor cells to dampen inflammation. Front Immunol 2022;13:933847. [DOI: 10.3389/fimmu.2022.933847] [Reference Citation Analysis]